Boston · Seed–Late Stage · 39 people tracked
Also known as 5AM VENTURE MANAGEMENT, LLC
Find your way into 5AM Ventures
4,446 people in our graph share verified history with the 5AM Ventures team — schools, employers, funds. One of them is your warm intro.
Investment thesis
5AM Ventures backs life science and biotech companies, concentrating on biopharmaceuticals, drug delivery technologies, and life science instruments. Its main strategy invests in private, early-stage therapeutic companies with an emphasis on Series A financings, while an Opportunities strategy targets small and mid-cap public and later-stage private biotech and life science companies. Through its internal '4:59' effort, the firm takes a hands-on approach to discovering, incubating, and funding breakthrough science, partnering with academics and entrepreneurs and often acting as an extension of the operating team to generate proof-of-concept data that supports a Series A round.
Source: firm website, verified Sep 15, 2026.
Team · 39 people
from the firm's website & public directories
Founder mafia
4 people who came through 5AM Ventures went on to found or lead other companies.
What they invest in
from 67 of 124 portfolio companiesBiotech ×58Healthtech ×32Medical Devices ×14Deep Tech ×7AI & Machine Learning ×6Digital Health ×6Enterprise Software ×2SaaS ×2
HQs:United States×62United Kingdom×1
Who they back
founder profiles across 17 portfolio companiesFounding team size:solo founder×92 founders×53 founders×3
Where their founders worked beforefrom 12 founders with career history
Vectura Group plc. ×2
Investments · 124 tracked
founders shown can be your intro pathBy year:2026 · 12025 · 62024 · 12023 · 22022 · 12021 · 122020 · 42019 · 42018 · 52017 · 32016 · 72015 · 865 dated
Entrada Therapeutics is a biotech company developing intracellular therapeutics based on its proprietary EEV Platform, aimed at reaching previously inaccessible or undruggable disease-causing targets inside cells.
BiotechHealthtechBoston, US
Natarajan Sethuraman(Executive Officer)inNerissa Kreher(Executive Officer)inKory Wentworth(Executive Officer)inDipal Doshi(Chief Executive Officer)inNathan Dowden(Executive Officer)inNatarajan Sethuraman, PhD(President of Research and Development)
Board seatKush M Parmar· per SEC Form D
Co-investorsAgent CapitalMPM BioImpactMRL Ventures FundRoche Venture FundTCG Crossover
Cabaletta Bio is a clinical-stage biotechnology company developing engineered T cell therapies for patients with autoimmune diseases.
BiotechHealthtechRadnor, US
Steven Nichtberger(Executive Officer, Director)inSteven Nichtberger, MD(Founder)inDan Geffken(Executive Officer)inAnup Marda(Chief Financial Officer)inMark Simon(Director)
Board seatBrian Daniels· per SEC Form D
Co-investorsBain Capital Life SciencesDeerfield Management Company
Camp4 Therapeutics develops antisense oligonucleotides targeting regulatory RNAs to increase gene expression and restore healthy protein levels for genetic diseases, with an initial focus on treating SYNGAP1-related developmental and epileptic encephalopathy.
BiotechCambridge, US
Richard Young(Director (Class II))JOSH MANDEL-BREHM(Executive Officer, Director)inJosh Mandel-Brehm(Chief Executive Officer and Director (Class III))in
BoardMICHAEL HIGGINS(Director)JORGE CONDE(Director)inAMIR NASHAT(Director)in
Board seatAndrew J. SchwabAndy Schwab· per SEC Form D
Co-investorsAndreessen HorowitzLongwood FundPolaris Partners
IDEAYA is a precision medicine oncology company developing first-in-class targeted therapies and rational drug combinations for molecularly defined, hard-to-treat cancers.
BiotechDigital HealthHealthtechMedical DevicesSouth San Francisco, US
Paul Stone(Executive Officer)inYujiro S. Hata(President, Chief Executive Officer and Director)
BoardTimothy Shannon(Director)inTerry Rosen(Director)Jeffrey Stein(Director)
Board seatJohn DiekmanBrian Daniels· per SEC Form D
Co-investorsCanaan PartnersNextech InvestBiotechnology Value FundWuXi Healthcare Ventures
Pulmatrix develops inhaled dry-powder therapies using its proprietary iSPERSE technology, which uses small, dense, dispersible particles to deliver respiratory and non-respiratory drugs via the respiratory system.
BiotechDeep TechHealthtechMedical DevicesFramingham, US
Anand Varadan(Director)inRichard Batycky(Director)Peter Ludlum(Interim CEO; Interim CFO)Hojabr Alimi(Executive Officer)Sameer Harish(Executive Officer)
BoardRichard Conley(Director)
Board seatScott Rocklage· per SEC Form D
Co-investorsALTITUDE LIFE SCIENCE VENTURESARCH Venture PartnersPolaris Partners
Rallybio is a clinical-stage biotech company developing therapies for people with severe and rare diseases, with a pipeline focused on complement dysregulation and hematology.
BiotechHealthtechNew Haven, US
Stephen Uden(Founder)inMartin W. Mackay(Chairman of the Board of Directors)inJon(Chief Financial Officer)
Board seatKush M ParmarPaula Soteropoulos· per SEC Form D
Co-investorsCanaan PartnersConnecticut InnovationsF-Prime CapitalMitsui Global InvestmentSolasta VenturesPivotal Life Sciences
Stoke Therapeutics develops RNA-based antisense oligonucleotides to treat severe genetic diseases by restoring protein expression through its TANGO platform, with a lead program in late-stage clinical development for Dravet syndrome and additional programs targeting other genetic disorders of the central nervous system and eye.
BiotechBedford, US
Adrian Krainer(Executive Officer, Director, Promoter)Isabel Aznarez(Executive Officer, Director, Promoter)inHuw Nash(Executive Officer)inIan F. Smith(Chief Executive Officer and Director)Jason Hoitt(Chief Patient Officer)inThomas E. Leggett(Chief Financial Officer)
Board seatArthur Tzianabos· per SEC Form D · $90M raise · filed Nov 2018
Co-investorsScion Life SciencesRTW Investments L.P.
Arvinas is a biopharmaceutical company developing PROTAC protein degrader therapies, with a pipeline focused on oncology and neurology.
BiotechHealthtechNew Haven, US
Sean Cassidy(Executive Officer)inManuel Litchman(Executive Officer, Director)inRandy Teel(President and Chief Executive Officer; Director)in
BoardStephen Squinto(Director)inLiam Ratcliffe(Director)inTim Shannon(Director)in
Co-investorsAccess BiotechnologyCanaan PartnersConnecticut InnovationsNextech InvestRA CapitalSolasta Ventures+1 more
Crinetics is a pharmaceutical company focused on discovering, developing, and commercializing therapies for endocrine diseases and endocrine-related conditions.
BiotechSan Diego, US
Richard Scott Struthers(Executive Officer, Director)Stephen F. Betz(Executive Officer)inStephen Betz(Chief Scientific Officer)inR. Scott Struthers(President, Chief Executive Officer and Director)inTobin Schilke(Chief Financial Officer)inIsabel Kalofonos(Chief Commercial Officer)in
Co-investorsForesite CapitalOrbiMedRA CapitalVivo Capital
Disc Medicine is a biopharmaceutical company developing therapies from discovery through clinical development for patients in need.
BiotechHealthtech
John Quisel(Chief Executive Officer)inJean Franchi(Chief Financial Officer)inJonathan Yu(Chief Operating Officer)inWill Savage(Chief Medical Officer)inPamela Stephenson(Chief Commercial Officer)inSteve Caffé(Chief Regulatory Officer)in
Co-investorsAccess BiotechnologyAtlas VentureBain Capital Life SciencesForesite CapitalFrazier Life SciencesOrbiMed+6 more
Enliven Therapeutics is a clinical-stage biopharmaceutical company that discovers and develops small molecule therapeutics using a precision medicine approach, with a focus on oncology and hematology.
BiotechHealthtechBoulder, US
Sam Kintz(Co-founder and Head of Pipeline)inJoe Lyssikatos(Co-founder and Research Fellow)Anish Patel(Co-founder and Chief Operating Officer)Rick Fair(Chief Executive Officer and Member of the Board of Directors)inHelen Collins(Chief Medical Officer)inBen Hohl(Chief Financial Officer and Head of Corporate Development)in
Co-investorsOrbiMedPfizer Venture InvestmentsRoche Venture FundARCH Venture PartnersBay City CapitalNew Enterprise Associates (NEA)+1 more
Q32 Bio is a biotechnology company developing therapies for autoimmune and inflammatory diseases, with a scientific focus on the complement system and immune regulation in conditions such as inflammation, autoimmunity and fibrosis.
BiotechHealthtech
Shelia Violette(Founder & Chief Scientific Officer)inMichael Holers(Co-founder)Jodie Morrison(Chief Executive Officer)inLee Kalowski(President & Chief Financial Officer)Maria Marzilli(Chief Business Officer)inDavid Appugliese(Senior Vice President, Head of People)in
Co-investorsAtlas VentureOrbiMedAgent CapitalCU Healthcare Innovation FundOUP (Osage University Partners)Sanofi Ventures+2 more
Rallybio is a clinical-stage biotechnology company developing therapies for severe and rare diseases, with a lead program in RLYB116, a C5 complement inhibitor in clinical development, and a preclinical program in RLYB332, a matriptase-2 antibody for iron overload disorders.
HealthtechFarmington, US
Jeffrey M. Fryer(Executive Officer, Director)Martin W. Mackay(Executive Officer, Director)Stephen Uden(Executive Officer, Director)
Co-investorsCanaan PartnersPivotal Life Sciences
Vor Biopharma is a biopharmaceutical company.
BiotechCambridge, US
Nathan Jorgensen(Executive Officer)Amy Mendel(Executive Officer)Robert Ang(Executive Officer, Director)Jean-Paul Kress(President, Chief Executive Officer and Chairman of the Board)in
BoardKush Parmar(Director)inJoshua Resnick(Director)
Co-investorsOUP (Osage University Partners)RA CapitalPureTech Health
Kinaset Therapeutics is a drug developer working on KN-002, a therapeutic candidate for treating severe asthma across patients regardless of the underlying cause of inflammation.
BiotechHealthtechMedfield, US
Roger Heerman(Chief Business/Operating Officer / Co-Founder)inFrazer Morgan(Chief Development Officer / Co-Founder)inRobert Clarke(Chief Executive Officer / Board Member / Co-Founder)Christopher O’Brien(Chief Medical Officer)
BoardJamil Beg(Director of the Issuer)inTom King(Director of the Issuer)
Co-investorsAtlas VentureRA CapitalEQT Life SciencesSixty Degree CapitalVivo CapitalGimv+3 more
Lifordi Immunotherapeutics develops treatments for immunology and rare diseases through discovery, clinical development, and commercialization.
BiotechDeep TechHealthtech
Arthur O. Tzianabos, Ph.D.(President and CEO)Naina Bhasin, Ph.D.(Chief Business Officer)
Co-investorsARCH Venture PartnersAtlas VentureSanofi Ventures
Precede Biosciences develops a blood-based diagnostic platform that profiles gene expression from cell-free DNA to reveal disease biology at the transcriptional level for drug developers and clinical trials.
AI & Machine LearningBiotechDigital HealthBoston, US
Rehan Verjee(Co-Founder, Chief Executive Officer, Board Director)inSylvan Baca(Co-Founder; Assistant Professor of Medicine, Dana-Farber Cancer Institute)inToni Choueiri(Co-Founder; Director, Lank Center for GU Oncology, Dana-Farber Cancer Institute)Matthew Freedman(Co-Founder; Professor of Medicine, Dana-Farber Cancer Institute)
Co-investorsIllumina VenturesOUP (Osage University Partners)Lilly Asia VenturesOsage University Partners
Soteria Biotherapeutics develops protein-based biotherapeutics and small molecules using its LITE Switch technology platform for drug discovery and development across oncology, immune-oncology, and inflammatory disease indications.
BiotechDeep TechHealthtechMedical DevicesWellness & FitnessSan Francisco, US
Jim Wells(Co-founder, Scientific Advisory Board Chair)Kristine M Ball(Executive Officer, Director)inZachary Hill(Executive Officer, Director)in
BoardNisha Marathe(Director)David Allison(Director)inKeno Gutierrez(Director)in
Co-investorsNovartis Venture FundRoche Venture FundVersant VenturesBioGeneration VenturesWestlake Village BioPartners
BlueLight Therapeutics develops novel drug molecules using a proprietary structure-based discovery platform targeting high-value therapeutic targets in life sciences.
AI & Machine LearningBiotechDeep TechSouth San Francisco, US
Ariel G. Notcovich(Founder & CEO)Mark Gallop(CSO)Mira Chaurushiya(CBO)Anjanabha Saha(VP, Discovery)
Co-investorsPfizer VenturesPfizer Venture Investments
Akouos is a precision genetic medicine company developing therapies for the inner ear to restore, improve, and preserve hearing.
BiotechHealthtechBrookline, US
Emmanuel Simons(Executive Officer, Director)william sewell(Founder)in
BoardEd Mathers(Director)inKush Parmar(Director)in
Board seatKush M ParmarArthur Tzianabos· per SEC Form D
Co-investorsEcoR1 CapitalNew Enterprise Associates (NEA)RA CapitalSofinnova VenturesCowen Healthcare InvestmentsFidelity Investments+1 more
Artiva Bio is a clinical-stage biotechnology company developing NK cell-based therapies for autoimmune diseases, designed to be manufactured at scale and delivered in community settings.
BiotechHealthtechMedical DevicesSan Diego, US
Jennifer Bush(Executive Officer)inThomas J. Farrell(Executive Officer)Fred Aslan(Executive Officer, Director)inJason Litten(Executive Officer)inEsther van den Boom(Executive Officer)Peter Flynn(Executive Officer)in
Board seatBrian Daniels· per SEC Form D
Co-investorsEcoR1 CapitalRA CapitalvenBio PartnersvenBio Global Strategic
Pharmaceutical company developing medicines and vaccines for patient health and treatment.
BiotechHealthtechSan Diego, US
Jeffrey Stein(Executive Officer, Director)Kevin Judice(Director)inKevin Forrest(Executive Officer)Dirk Thye(Executive Officer)inKen Bartizal(Executive Officer)inPaul Daruwala(Executive Officer)in
Board seatScott Rocklage· per SEC Form D
Co-investorsAisling CapitalBain Capital Life SciencesFrazier Life SciencesRA CapitalVivo CapitalCanaan Partners+1 more
Ensoma is a genomic medicine company developing a platform for in vivo engineering of hematopoietic stem cells (HSCs), combining an off-the-shelf delivery system with a gene engineering toolkit intended to treat diseases with a one-time treatment.
BiotechHealthtechMedical DevicesBoston, US
Albert Seymour(Director)
BoardKush Parmar(Executive Officer, Director)inStephen Knight(Director)in
Board seatKush M ParmarPaula Soteropoulos· per SEC Form D
Co-investorsAju IB Invesment CorporationCatalio Capital Management, LPDelos CapitalF-Prime CapitalSolasta VenturesAlexandria+7 more
Latigo Biotherapeutics is a clinical-stage biopharmaceutical company developing non-opioid pain medicines designed to stop pain transmission without addiction risk.
BiotechHealthtechMedical DevicesThousand Oaks, US
Nima Farzan(Executive Officer, Director)Tim Lugo(Executive Officer)
BoardBeth Seidenberg(Director)inJim Tananbaum(Director)inKevin Raidy(Director)
Board seatDeborah Palestrant· per SEC Form D
Co-investorsAccess BiotechnologyAscenta CapitalForesite CapitalKern Capital, LLCSanofi VenturesWestlake Village BioPartners
Pioneering the development of prescription digital therapeutics.
HealthtechBoston, US
Corey McCann(Executive Officer, Director)inAntoun Nabhan(Executive Officer)Christopher Guiffre(Executive Officer)
BoardAndrew Schwab(Director)inTimothy Petersen(Director)inZack Lynch(Director)in
Board seatAndrew J. Schwab· per SEC Form D · $20.4M raise · filed Feb 2016
Co-investorsJAZZ Venture PartnersArboretum VenturesGeneral CatalystOCA VenturesSeyen CapitalSoftBank Group+1 more
.png)
Seattle, US
Ronald Seubert(Executive Officer, Director, Promoter)Evan Castiglia(Executive Officer)inJoseph Victor(Executive Officer, Director)Frank Witney(Director)Eric Kaldjian(Executive Officer)
BoardRobert Shepler(Director)in
Board seatAndrew Schwab· per SEC Form D
Co-investorsArboretum VenturesF-Prime CapitalSofinnova VenturesTelegraph Hill Partners
Alexza Pharmaceuticals, now operating as Nova Pneuma, Inc., is a pharmaceutical company that developed the Staccato One Breath Technology drug-delivery platform and markets the commercial product Adasuve.
BiotechHealthtechMountain View, US
Edwin S Kamemoto(Executive Officer)inMark K Oki(Executive Officer)inThomas B King(Executive Officer, Director)inMichael J Simms(Executive Officer)James V Cassella(Executive Officer)Robert A Lippe(Executive Officer)in
Co-investorsNew Enterprise Associates (NEA)
Aprea Therapeutics is a biopharmaceutical company developing novel cancer therapies targeting DNA damage response pathways to treat solid tumors including ovarian, colorectal, prostate, and breast cancers.
BiotechDigital HealthMedical DevicesDoylestown, US
John P. Hamill(Executive Officer)inOren Gilad(Chief Executive Officer, President)in
BoardJean-Pierre Bizzari(Director)Gabriela Gruia(Director)Rifat Pamukcu(Director)Bernd Seizinger(Director)
Co-investorsHealthCapVersant Ventures
BiotechSan Francisco, US
Matthew Patterson(Executive Officer, Director)in
BoardJonathan Silverstein(Director)inSteve Squinto(Director)inKush Parmar(Director)inJonathan Leff(Director)Thomas Woiwode(Director)
Co-investorsAsset Management CompanyRA CapitalvenBio PartnersDeerfield Management CompanyOrbiMedVenrock
Bioz provides AI-powered widgets for suppliers that display scientific publication data to build trust and improve sales conversion.
AI & Machine LearningEnterprise SoftwareSaaSLos Altos, US
Daniel Levitt(Executive Officer, Director)Karin Lachmi(Executive Officer, Director)Karin L.(Founder)in
Co-investorsPerot Jain
Camp4 is a biotechnology company focused on genetic research and neurology, leveraging expertise in genomics and neuroscience for therapeutic development.
AI & Machine LearningBiotech
BoardChristopher Walsh, MD, PhD(Scientific Advisor)
Co-investorsAndreessen HorowitzFlucas Ventures
HealthtechHayward, US
GUY DIPIERRO(Director)inALAN LEVY, PH.D.(Executive Officer, Director)ANTHONY RIMAC(Executive Officer)ALAN LEVY(Executive Officer, Director)
BoardELIZABETH ROCKETT(Director)WENDE HUTTON(Director)in
Co-investorsEmergent Medical Partners, LLPFountain Healthcare PartnersKaiser Permanente VenturesMission Bay CapitalCanaan PartnersGE Ventures
BiotechBurlingame, US
Mark Rolfe(Executive Officer)Laura Shawver(Executive Officer, Director)inTimothy Smith(Executive Officer)
BoardAlfred Scheidegger(Director)inPeter Thompson(Director)inCarol Gallagher(Director)in
Co-investorsAstellas Venture Management LLCNew Enterprise Associates (NEA)Nextech InvestClarus VenturesOrbiMedOsage University Partners+1 more
Dianthus Therapeutics develops antibody-based therapies for patients with severe autoimmune diseases, including its lead complement C1s inhibitor claseprubart (DNTH103) and a bifunctional inhibitor DNTH212 designed for self-administered subcutaneous injection.
BiotechHealthtechWaltham, US
Jonathan Violin(Executive Officer, Director)inKenneth Evan Thompson(Executive Officer)
BoardLeon Moulder(Director)
Extracellular is a biomanufacturing company that helps cell-based product developers in cultivated meat, plant cell culture, and bioactives accelerate discovery, overcome production challenges, and commercialize their products.
Advanced ManufacturingBiotechFoodTechNew Materials
Will Milligan(CEO & Founder)in
Co-investorsBig Idea VenturesFFFNewland SyndicateUnruly CapitalAgent CapitalCatalio Capital Management+8 more
GlycoEra develops glycan-based therapeutics, applying glycoengineering technology to create biologic drugs.
BiotechHealthtechNewton, US
Ganesh V. Kaundinya(President & CEO)in
Co-investorsCatalio Capital Management, LPLifeArc VenturesRoche Venture FundSixty Degree CapitalSofinnova PartnersAgent Capital+1 more
Clinical-stage genetic medicines company using human-derived AAV vectors and nuclease-free gene editing for rare diseases.
BiotechBedford, US
Siyamak Rasty(Executive Officer)Albert Seymour(Executive Officer)
BoardSteven Gillis(Director)Arthur Tzianabos(Executive Officer, Director)Kush Parmar(Director)inRichard Gregory(Director)
Co-investorsARCH Venture PartnersOUP (Osage University Partners)AlexandriaDeerfield Management CompanyHBM Healthcare InvestmentsMaverick Ventures+4 more
Impel Pharmaceuticals develops therapies for diseases with high unmet medical needs by pairing established drugs with its proprietary upper-nasal drug delivery technology.
BiotechHealthtechMedical DevicesSeattle, US
John D. Hoekman(Executive Officer, Director)in
BoardMichael Hite(Director)Stewart Parker(Director)
Co-investorsB Capital GroupvenBio Global StrategicvenBio PartnersWestlake Village BioPartners
.jpeg){kind=logo}
Inipharm is a clinical-stage biopharmaceutical company developing small-molecule inhibitors targeting HSD17B13 to treat severe fibrotic liver diseases, including MASH and other conditions with established genetic validation.
BiotechHealthtechMedical Devices
Brian Farmer(Co-Founder, Chief Executive Officer)inHeather Hsu, PhD(Co-Founder, Chief Scientific Officer)Michael Gallatin, PhD(Co-Founder, SAB Chair)Chuhan Chung(Chief Medical Officer)in
Co-investorsFrazier Life SciencesFrazier Healthcare PartnersWu Capital
The page promotes "MEGA55", an Indonesian-language online gaming/gambling platform offering a variety of games with instant-win rewards and local digital payment methods.
Gaming
Co-investorsSanofi Ventures
Karius is a company that provides microbial cell-free DNA (mcfDNA) metagenomic sequencing services for research and clinical applications.
AI & Machine LearningBiotechDigital HealthMedical DevicesSan Francisco, US
Alec Ford(Chief Executive Officer)in
Co-investorsDCVC (Data Collective)Khosla VenturesLightspeed Venture PartnersSoftBank Vision Fund
BiotechBoston, US
Nagesh Mahanthappa, Ph.D.(Director)Luba Greenwood(Director)in
BoardAmir Nashat, Ph.D.(Treasurer and Secretary)Susan Langer(President)Thomas J. Cahill(Director)
Co-investorsCathay HealthNewpath PartnersPolaris Partners
Platform addressing PR industry complexity and scaling publisher relationships.
Co-investorsOIF VenturesOur Innovation FundVolition Capital
Magnetic Particle Imaging (MPI) is an imaging technology that detects iron oxide nanoparticle tracers using time-varying magnetic fields to create medical images with high contrast and sensitivity.
Deep TechHealthtechMedical Devices
Co-investorsEvolution VC PartnersInnolinks VenturesSand Hill AngelsShangBay Capital LLCCelesta CapitalWestlake Village BioPartners
nChroma Bio develops in vivo targeted delivery and genetic engineering technologies for genetic medicine applications.
BiotechDeep TechMedical Devices
Luke Gilbert, PhDKeith Joung, MD, PhDDavid Liu, PhDAngelo Lombardo, PhDLuigi Naldini, MD, PhDJonathan Weissman, PhD
Co-investorsAtlas VentureNewpath PartnersARCH Venture PartnersDCVC (Data Collective)F-Prime CapitalGV (Google Ventures)+2 more
Neurogastrx is a biopharmaceutical company developing therapies for patients with gastrointestinal disorders.
BiotechHealthtechWoburn, US
Cyril De Colle(Founder)inCYRIL DE COLLE(Executive Officer, Director)inJAMES DETORE(Executive Officer)JAMES O'MARA(Executive Officer, Director)inPAUL ROGERS(Executive Officer)in
BoardDAVID ALLISON(Director)in
Co-investorsOrbiMedSamsara BioCapitalvenBio PartnersVivo CapitalRTW Investments L.P.venBio Global Strategic+1 more
NodThera develops clinical-stage small-molecule therapies targeting inflammation for cardiometabolic and neuroinflammatory diseases, including cardiovascular disease, metabolic dysfunction, and neuroinflammation.
BiotechHealthtech
Geoff McDonough(Executive Team / Board)inChris Guiffre(Executive Team)inAlan P. Watt(Executive Team)inJyothis George(Chief Medical Officer)inNick Clarke(Executive Team)in
Co-investorsEpidarex CapitalF-Prime CapitalSanofi VenturesSofinnova Partners
Co-investorsAndera PartnersAngelini VenturesCDP Venture CapitalIndaco Venture PartnersM VenturesXGEN Venture+1 more
South San Francisco biotech engineering commensal gut bacteria into controllable live therapeutics for chronic diseases.
Daly City, US
Weston Whitaker(Executive Officer, Director, Promoter)William DeLoache(Director)Samuel Smits(Director)
BoardElizabeth Stanley(Director)
Co-investorsAlta PartnersCerity Partners VenturesAlexandriaDCVC (Data Collective)DCVC Bio
Radionetics develops small molecule radiopharmaceuticals targeting GPCRs for cancer therapy and diagnosis, using a precision medicine approach that combines radioisotopes with potent, selective ligands.
AI & Machine LearningBiotechDeep TechMedical DevicesSan Diego, US
Brett Ewald(Chief Operating Officer, Founding Member)inAlyssa Levin(Chief Financial Officer)inPaul Grayson(Chief Executive Officer)in
Co-investorsFrazier Life SciencesDCVC Bio
BiotechMenlo Park, US
Brett Ewald(Executive Officer)inUmesh Gangadharmath(Executive Officer)inIstvan Molnar(Executive Officer)inYunfei Zhu(Executive Officer)Ana Kusnetzow(Executive Officer)inScott Struthers(Director)
Co-investorsDCVC (Data Collective)Frazier Life SciencesDCVC BioFrazier Healthcare PartnersWestlake Village BioPartners
Renasant Bio is a biopharmaceutical company developing oral small molecule corrector and potentiator therapies to restore the function of polycystin 1 and 2 proteins in autosomal dominant polycystic kidney disease (ADPKD).
BiotechHealthtechBerkeley, US
Jeremy Reiter(Scientific Co-Founder)Markus Delling(Scientific Co-Founder)Thomas Gustafson(Executive Officer)inEmily Conley(Executive Officer, Director)in
BoardEvan Caplan(Director)inCharlotte McKee(Director)
Co-investorsOrbiMedAtlas VentureQiming Venture Partners USA
scPharmaceuticals was a commercial-stage biopharmaceutical company that developed FUROSCIX, an FDA-approved subcutaneous formulation of the diuretic furosemide for treating fluid overload in heart failure and kidney disease patients.
BiotechLexington, US
Pieter Muntendam(Executive Officer, Director)
BoardMette Kirstine Agger(Director)Kush Parmar(Director)inDorothy Coleman(Director)Leonard Schaeffer(Director)
Soteria provides cybersecurity advisory services and solutions, including managed detection and response (MDR), virtual CISO support, domain monitoring, and Microsoft 365 risk management.
CybersecurityEnterprise SoftwareSaaSCharleston, US
Glenn Starkman(Co-Founder)inCHRISTOPHER O'ROURKE(Executive Officer)
Co-investorsCheckmate Capital Group LLCRoche Venture Fund
BiotechResearch Triangle Park, US
Andrew Jordan(Executive Officer, Director)John Taylor(Executive Officer, Director, Promoter)Robert Tarran(Director)
BoardDonald Rose(Director)
Co-investorsCanaan PartnersHatteras Venture Partners
BiotechSan Diego, US
Alain Baron(Executive Officer, Director)JeenJoo Kang(Director)Robert Tjian(Director)Marcus Boehm(Executive Officer)
BoardAndrew Schwab(Director)in
Co-investorsAvego BioScience CapitalNew Enterprise Associates (NEA)OUP (Osage University Partners)Sanofi VenturesThe Column GroupAbingworth+3 more
TMRW Life Sciences builds an FDA-cleared automated platform for managing and storing frozen eggs and embryos, using RFID tracking and an "ivfOS" digital database to monitor and secure specimens.
Digital HealthFemTechHealthtechMedical DevicesNew York, US
Joshua Abram(Director)inTara Comonte(Director)inAlan Murray(Director)in
BoardAndrew Schwab(Director)Vinay Shah(Director)Emily Drabant Conley(Director)in
Co-investorsGV (Google Ventures)TRANSFORMATION CAPITALWhat If Ventures
VBI Vaccines is a biopharmaceutical company developing vaccine candidates using virus-like particle (VLP) platforms, including proprietary enveloped VLP and mRNA-launched eVLP technologies.
BiotechHealthtechCambridge, US
Marc Kirchmeier(Vice President, Formulation Development)Egidio Nascimento(Chief Financial Officer)inDavid Anderson(Senior Vice President, Research)inJeff Baxter(President and Chief Executive Officer)inAdam T. Buckley(Vice President, Business Development)inMurray G. Smith(Executive Officer)
Co-investorsARCH Venture PartnersClarus VenturesK2 HealthVentures
Viveve publishes evidence-based health guides covering six core topics—heart health, women's health, nutrition, hormones, sexual health, and aging—written without pseudoscience or supplement marketing.
Digital HealthHealthtechMedia & EntertainmentWellness & Fitness
Co-investorsAvoro Capital Advisors
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Agilis BiotherapeuticsBird Rock BioIgenica BiotherapeuticsKinestral TechnologiesPrecision NanoSystemsPulmatrix OperatingPurigen Biosystems, Inc.RennoviaAchaogenAdverum BiotechnologiesAmbrxAtterocorAudentesBellerophonBlueLight TherapeuticsCalibriumCellular ResearchCeterixChronoCinCorCinCor PharmaCleave TherapeuticsDeverraDVSEntradaEnvoyEpirusEscient PharmaceuticalsExpansion TherapeuticsFaradayFellow HealthFlexionGenePeeksHALIO, INC.IgenicaIkariaIlypsaInclineLatigoLifordiMarcadiaMendraMiikanaMillendoNido BioNoviraNovira TherapeuticsPanomicsPearPearlPhaseRxPhenomixPNIPortalProlynxPurigenRelypsaReprotechScientist.comSemprusSemprus BioSciencesSkyeSurrozenSynosiaWildcat
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Exits · 36
15 IPOs · 21 acquisitions · showing 35Entrada Therapeutics, Inc.NASDAQ: TRDACabaletta BioNASDAQ: CABACamp4 Therapeutics CorpNASDAQ: CAMPIdeaya BiosciencesNASDAQ: IDYAPulmatrixNASDAQ: PULMRallybio, LLCNASDAQ: RLYBStoke TherapeuticsNASDAQ: STOKArvinas Holding Co. LLCNASDAQ: ARVNCrineticsNASDAQ: CRNXDisc MedicineNASDAQ: IRONEnliven TherapeuticsNASDAQ: ELVNQ32 BioNASDAQ: QTTBRallybio HoldingsNASDAQ: RLYBVor BiopharmaNASDAQ: VORBird Rock Bioacq. by Skye BioscienceAmbrxacq. by Johnson & JohnsonAudentesacq. by Astellas PharmaCalibriumacq. by Novo NordiskCellular Researchacq. by Becton, Dickinson and Company (BD)Ceterixacq. by Smith+NephewFlexionacq. by Pacira BioSciences, Inc.Igenicaacq. by Pierre FabreIkariaacq. by Mallinckrodt PharmaceuticalsMarcadiaacq. by RocheMiikanaacq. by EntreMed, Inc. (now CASI Pharmaceuticals)Noviraacq. by Johnson & Johnson (Janssen Pharmaceutical Companies)Novira Therapeuticsacq. by Johnson & Johnson (Janssen)Panomicsacq. by AffymetrixPhaseRxacq. by Roivant SciencesPurigenacq. by Bionano GenomicsRelypsaacq. by Galenica (Vifor Pharma)Scientist.comacq. by GHO Capital PartnersscPharmaceuticalsacq. by MannKind CorporationSemprusacq. by TeleflexSynosiaacq. by Biotie Therapies
Portfolio news
latest coverage across their companiesVor Biopharma · defenseworld.net · Sep 3, 2026
Enliven Therapeutics · tickerreport.com · Aug 21, 2026
Cidara Therapeutics · tradingkey.com · Aug 20, 2026
Dianthus Therapeutics · tickerreport.com · Aug 17, 2026
Latigo Bio · labusinessjournal.com · Aug 17, 2026
Crinetics · tipranks.com · Aug 14, 2026
Cabaletta Bio · stocktitan.net · Aug 14, 2026
IPO stake values · per SEC filings · 7
Value of this firm's stake in each portfolio company at its IPO price, from the prospectus principal-stockholder table.
| Company | Owned | IPO price | At IPO | Stake value |
|---|---|---|---|---|
| Vor Biopharma | 17.2% | $18.00 | Feb 2021 | $110.5M |
| Q32 Bio | 18.6% | $16.00 | Mar 2018 | $107.6M |
| Entrada Therapeutics, Inc. | 13.9% | $20.00 | Nov 2021 | $83.2M |
| Rallybio, LLC | 11.5% | $13.00 | Jul 2021 | $46.5M |
| Rallybio Holdings | 11.5% | $13.00 | Jul 2021 | $46.5M |
| Cabaletta Bio | 13.7% | $11.00 | Oct 2019 | $35.4M |
| Ideaya Biosciences | 13.9% | $10.00 | May 2019 | $27.1M |
Source: SEC S-1 / 424B prospectus filings. Stake value = shares beneficially owned × the initial public offering price, as disclosed — a market value at IPO, not a return multiple (the firm's original cost is not disclosed).
Frequently asked questions
- How many investments has 5AM Ventures made?
- 5AM Ventures has 124 tracked investments, 36 of which have exited, including 7 dated in the last 24 months.
- What stage does 5AM Ventures invest at?
- 5AM Ventures invests at the Seed, Series A, Growth, Late Stage stages.
- What is 5AM Ventures's typical check size?
- 5AM Ventures typically writes checks of $100K – $4M.
- What sectors does 5AM Ventures focus on?
- 5AM Ventures focuses on Biotech, Digital Health, Healthtech, Longevity, Medical Devices.
- Where is 5AM Ventures located?
- 5AM Ventures is headquartered in Boston, US.
- Does 5AM Ventures lead rounds?
- Yes, 5AM Ventures leads investment rounds.
- Who does 5AM Ventures co-invest with?
- 5AM Ventures most often shares deals with RA Capital, Frazier Life Sciences, F-Prime Capital, among 63 tracked co-investors.
Co-investors · 40
OrbiMed is a global healthcare-focused investment firm providing financing and operational support to companies across biopharmaceuticals, medical devices, digital health, diagnostics, and healthcare services.
RA Capital is a multi-stage investment firm focused on healthcare, life sciences, and planetary health, investing across public and private markets and creating new companies through its Raven incubation platform.
Canaan Partners is a venture capital firm with over 30 years of history, backing companies across technology and healthcare sectors through close, hands-on partnerships with founders.
Sanofi Ventures is the corporate venture capital arm of Sanofi, investing in early-stage biotech and digital health companies focused on improving human health. It serves as Sanofi's entry point into the innovation ecosystem.
Westlake Village BioPartners is a Los Angeles-based life science venture capital firm that builds and incubates biotech companies around top entrepreneurs, providing hands-on support from ideation through clinical and commercial stages.
Atlas Venture is a life sciences venture capital firm with three decades of experience investing in and building biotech and medical innovation companies, including startups launched from its own incubator.
ARCH Venture Partners is a venture capital firm that invests in and helps build transformational companies, with a strong focus on the life sciences and biotechnology sector.
OUP (Osage University Partners) is a venture firm that invests in science-driven startups commercializing deep technology innovations emerging from university and breakthrough research.
New Enterprise Associates (NEA) is a venture capital firm that invests in and provides long-term support to founders building new companies.
DCVC (Data Collective) is a deep tech venture capital firm that backs entrepreneurs using computational approaches to solve large-scale real-world problems across many industries.
F-Prime Capital is an early-stage-focused investment firm backing companies across life sciences, technology, healthtech and services, and crypto.
Polaris Partners is a venture capital firm that partners with biotech and healthcare entrepreneurs to build transformational companies.
▶28 more co-investors
Sofinnova PartnersvenBio PartnersThe Column GroupForesite CapitalVersant VenturesDeerfield Management CompanyNextech InvestAndreessen HorowitzAbingworthArboretum VenturesFrazier Healthcare PartnersConnecticut InnovationsAlta PartnersLongwood FundTelegraph Hill PartnersKleiner PerkinsVenrockEQT Life SciencesSR One Capital ManagementAndera PartnersHatteras Venture PartnersIllumina VenturesForbionNew Leaf Venture PartnersHealthQuest CapitalJMI EquityAltitude Ventures Management, LlcHive Ventures
Firms observed investing alongside 5AM Ventures, from public investor directories. Shared companies are the overlap with 5AM Ventures's recorded portfolio.
Similar investors
GV (Google Ventures) is a venture capital firm that has invested in artificial intelligence and machine learning since its early days, building a global portfolio of more than 100 AI companies across infrastructure, life sciences, and applications.
Khosla Ventures is a venture capital firm founded by Vinod Khosla.
JAZZ Venture Partners is a venture capital firm investing in companies at the intersection of technology, neuroscience, and human performance, spanning digital health, biosciences, and AI.
Novo Holdings is the holding and investment company that manages the assets of the Novo Nordisk Foundation, serving as controlling shareholder of Novo Nordisk and Novonesis. It invests in life science companies across all stages and manages a diversified portfolio of equities, bonds, real estate, infrastructure and private equity.
Lumira Ventures is a North American life sciences venture capital firm that partners with mission-driven entrepreneurs to build companies developing and commercializing healthcare products for patients.